188 results on '"Ravenni N"'
Search Results
2. P221 Airways viral infections in children and adults with cystic fibrosis
3. 71 No SARS-CoV-2 viral upper and lower airways infection in cystic fibrosis: evaluation of clinical outcomes
4. 611 Quantity-not-sufficient sweat test in children undergoing newborn screening for cystic fibrosis
5. 713 Isolation of non-aeruginosa Pseudomonas from cystic fibrosis airways: a consequence of elexacaftor-tezacaftor-ivacaftor therapy? Results of a multicenter study
6. EPS9.10 Could anti-Pseudomonas aeruginosa antibodies be a useful marker in monitoring the effect of ETI treatment on airways’ microbiology in cystic fibrosis (CF)?
7. WS13.03 Microbiology of upper and lower airways of cystic fibrosis (CF) patients in stable conditions and in lung transplant patients
8. 569 Use of anti-Pseudomonas aeruginosa antibodies and characterization of P. aeruginosa isolates for early antibiotic treatment monitoring
9. 490 Evaluation of the BioFire FilmArray Pneumonia Panel Plus for diagnosis of lower respiratory tract infections in people with cystic fibrosis who have undergone lung transplantation
10. 493 Bacterial and viral upper and lower airways infection in people with cystic fibrosis in stable condition
11. P142 Upper and lower airways microbiological status in cystic fibrosis patients in stable conditions and in lung transplant patients
12. P164 Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis: cross-sectional analysis and effect of elexacaftor/tezacaftor/ivacaftor
13. P146 Microbiological diagnostic procedures for respiratory cystic fibrosis samples: results of a survey in Italian laboratories
14. P118 Airways respiratory viral infections in cystic fibrosis
15. Application of multiplex single nucleotide primer extension (mSNuPE) to the identification of bacteria: The Burkholderia cepacia complex case
16. IN VITRO ACTIVITY OF TEMOCILLIN ON MULTIRESISTANT P. AERUGINOSA ISOLATED FROM CYSTIC FIBROSIS PATIENTS: 324
17. EVALUATION OF ANTIBODY TITER ANTI-P. AERUGINOSA IN PATIENTS UNDERGOING ERADICATION THERAPY: 231
18. P163 Effects of the SARS-CoV-2 pandemic on attendance at the cystic fibrosis centre and the definition of the microbiological status of cystic fibrosis patients in Tuscany
19. PSEUDOMONAS AERUGINOSA ERADICATION IN CYSTIC FIBROSIS: FINAL RESULTS OF A RANDOMIZED MULTICENTER STUDY OF TWO DIFFERENT EARLY ANTIBIOTIC TREATMENT PROTOCOLS: 291
20. PSEUDOMONAS AERUGINOSA MICROBIOLOGICAL STATUS AND EMERGENCE OF OTHER PATHOGENS AFTER EARLY ERADICATION TREATMENT IN CYSTIC FIBROSIS: A POST-TRIAL FOLLOW-UP: 292
21. P018 Symptoms at diagnosis and genotype of false negatives (FNs) in newborn screening (NBS) in Tuscany: experience over 26 years
22. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?
23. EVOLUTION OF ACQUIRED RESISTANCE MECHANISMS IN PSEUDOMONAS AERUGINOSA ISOLATED FROM CHRONICALLY-INFECTED CYSTIC FIBROSIS PATIENTS: 436
24. CORRELATION BETWEEN ANTIMICROBIAL SUSCEPTIBILITY AND GENOMOVAR STATUS OF BURKHOLDERIA CEPACIA-COMPLEX MULTIRESISTANT STRAINS ISOLATED FROM A CYSTIC FIBROSIS POPULATION: 410
25. EPIDEMIOLOGY OF PSEUDOMONAS AERUGINOSA STRAINS ISOLATED FROM RE-COLONISATION EPISODES IN PATIENTS FOLLOWING EARLY ERADICATION THERAPY: 413
26. ANTI- PSEUDOMONAS AERUGINOSA IGA AND IGG ANTIBODIES IN THE SERUM OF CYSTIC FIBROSIS PATIENTS PRIOR TO BACTERIA ISOLATION: 328
27. High frequency of adverse effects to antibiotics in cystic fibrosis patients and fast protocol of intravenous desensitization
28. P041 Multi-drug resistant Pseudomonas aeruginosa strains in cystic fibrosis and FEV1 decline
29. 101 Longitudinal study of methicillin-resistant Staphylococcus aureus genetic background isolated from cystic fibrosis patients
30. AB0364 A Novel Approach for Rheumatoid Arthritis: Results of The Ongoing Clinical Trials with The Fully Human Immunocytokine Dekavil (F8-IL10)
31. 55 CA-MRSA and HA-MRSA persistent infection and pulmonary function: a multicenter longitudinal study
32. SAT0196 Dekavil (F8-IL10), A Novel Therapeutic Approach for Rheumatoid Arthritis: Ongoing Phase IB Clinical Trial Results
33. 73 Impact of community-acquired MRSA and hospital-acquired MRSA on pulmonary function of CF patients
34. Pseudomonas aeruginosa e metallo-beta-lattamasi in pazienti affetti da fibrosi cistica: prevalenza e persistenza nel tempo
35. Metallo-beta-lactamase-producing Pseudomonas aeruginosa in a cystic fibrosis patient: persistence over a 6-year period
36. Epidemiologia molecolare di Burkholderia cepacia complex: un modello per un confronto di metodi
37. EPIDEMIOLOGIA MOLECOLARE DI BURKHOLDERIA CEPACIA COMPLEX: UN MODELLO PER UN CONFRONTO DI METODI
38. Transmission of Burkholderia cepacia complex: Evidence for new epidemic clones infecting cystic fibrosis patients in Italy RID B-7967-2009
39. Transmission of Burkholderia cepacia complex: evidences of new epidemic clones in Italian CF population
40. 121 Anti-Pseudomonas aeruginosa antibodies and microbiological outcome in not chronically infected patients
41. 57 Emergence of a Panton-Valentine leukocidin (PVL) positive MRSA strain in cystic fibrosis (CF) patients
42. 88 Use of MALDI-TOF-MS for identification of anaerobic bacteria in CF patients
43. Transmission of Burkholderia pyrrocinia: a report of two outbreaks involving Italian cystic fibrosis patients
44. Trasmission of B. pyrrocina: a report of two outbreaks involving italian cystic fibrosis patients
45. 128 Pseudomonas aeruginosa infecting lung-transplanted cystic fibrosis patients: A longitudinal study
46. VALIDATION OF NEUROTENSIN TETRA-BRANCHED PEPTIDES AS TUMOR TARGETING AGENTS IN PANCREAS, COLON AND BLADDER CARCINOMA
47. TUMOR SELECTIVE DRUG DELIVERY BY NEUROTENSIN BRANCHED PEPTIDES
48. 1219 POSTER Turning Traditional Cytotoxic Drugs Into Tumour-selective Agents
49. 46 Delay in meconium emission: should it be considered a risk for cystic fibrosis?
50. 225 Analysis of bacterial pathogens before and after lung transplantation in cystic fibrosis patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.